Skip to content

Author

Andreas Krämer

We have 3 of 44 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells.

Histone lysine demethylase 4 (KDM4) enzymes are frequently overexpressed in cancer and are considered to be promising therapeutic targets. QC6352, which is widely used as a best-in-class KDM4 chemical probe, shows potent antitumor activity across cancer models. Using comprehensive chemical biology approaches in gliobla...

Jayden Sterling, Jacinda R. Holtsmark, George L. Joun et al. · 1 citation
Open access Oct 2026

Development of Organocatalytic Switches of OGG1 that Protect Mitochondria under Oxidative Stress

Mitochondrial dysfunction is a major component of neurodegeneration. The mitochondrial genome is prone to oxidative damage, and repair proteins are important to maintain mitochondrial DNA integrity. OGG1 initiates base excision repair of oxidative DNA lesions in both nuclear and mitochondrial genomes. While inhibitor...

Maeve Long, James R. Tribble, Rahul Upadhyay et al. · 0 citations
Open access Apr 2026

Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib Leads to Potent and Selective Quinoline-Based HIPK4 Inhibitor AZ137

A rational design strategy utilizing macrocyclization of a bosutinib-based scaffold provides a foundational framework for the validating HIPK4 as a therapeutic target and a high-quality resource to elucidate its roles in normal physiology and disease.

Athina Zerva, Nicolai D. Raig, Zai-Le Zhuang et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.